drugset
drugset / Trial / NCT01554579

A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee

NCT01554579 ↗

Phase 2 Completed 171 enrolled Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy of a single dose level of gefapixant (AF-219/MK-7264) in subjects with moderate to severe pain associated with osteoarthritis (OA) of the knee compared with placebo after 4 weeks of treatment. The study will also assess the safety and tolerability, changes in physical function, stiffness, treatment response and health outcomes.

Timeline

Start
2012-03-29
Primary completion
2013-11-11
Completion
2013-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefapixant Small molecule — —

Indications

osteoarthritis, knee